Faricimab: all 44 studies that test it

Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study)Not yet recruitingNCT07753616Phase 4
• A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis SyndromeRecruitingNCT07695298Phase 4
• Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled TrialNot yet recruitingNCT07681167Phase 2
• Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar RanibizumabRecruitingNCT07520045Not applicable
• Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal VasculopathyRecruitingNCT07461441Phase 3
• A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)RecruitingNCT07425522Phase 1
• Efficacy of Faricimab in Patients With Subretinal Hyper-reflective MaterialRecruitingNCT07403825Phase 4
• Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular DegenerationRecruitingNCT07367282Phase 4
• Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial SettingRecruitingNCT07249216Not applicable
• Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular NeovascularizationNot yet recruitingNCT07187804Phase 4
• Impact of Intravitreal Faricimab on Renal Function in Diabetic PatientsRecruitingNCT06929507Not applicable
• Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment IntervalsRecruitingNCT06875245Phase 4
• Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRRecruitingNCT06790784Phase 3
• Faricimab Quarterly Maintenance for Neovascular Age Related Macular DegenerationRecruitingNCT06742307Phase 4
• Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)RecruitingNCT06709339Phase 4
• Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO PatientsRecruitingNCT06572553Phase 2/3
• Pre-operative Vabysmo in Patients With Non-clearing Vitreous Hemorrhage Secondary to Proliferative Diabetic RetinopathyEnrolling by invitationNCT06191094Phase 4
• Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation RetinopathyRecruitingNCT05844982Phase 3
• Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural OutcomeRecruitingNCT00346814Phase 2/3
• A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled SyringeCompletedNCT05569148Phase 3Results posted
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationCompletedNCT04777201Phase 3Results posted
• A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With FaricimabCompletedNCT04597918Phase 2Results posted
• A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular EdemaCompletedNCT04432831Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)CompletedNCT03823300Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)CompletedNCT03823287Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular EdemaCompletedNCT03622593Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)CompletedNCT03622580Phase 3Results posted
• Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular DegenerationCompletedNCT03038880Phase 2Results posted
• A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular EdemaCompletedNCT02699450Phase 2Results posted
• A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)CompletedNCT02484690Phase 2Results posted
• Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab InjectionCompletedNCT07144865Not applicable
• Intravitreal Faricimab in Patients With Refractory Macular EdemaCompletedNCT07093385Phase 2
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaCompletedNCT06850922Phase 1/2
• A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationActive, not recruitingNCT06795048Phase 4
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedNCT06176352Phase 3
• Safety and Efficacy of Faricimab in Patients With NPDRCompletedNCT05681884Phase 2
• Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to AfliberceptStatus unknownNCT05610488Phase 4
• Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled TrialActive, not recruitingNCT05610319Phase 4
• A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular EdemaActive, not recruitingNCT05224102Phase 4
• BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular DegenerationStatus unknownNCT04882956Not applicable
• A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular DegenerationCompletedNCT01941082Phase 1
• Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High MyopiaCompletedNCT00967850Phase 3
• Intravitreal Bevacizumab in Agioid StreaksCompletedNCT00406250Phase 1
• Bevacizumab and Retinal Vascular OcclusionsWithdrawnNCT00347711Phase 3

← Faricimab overview